Missed the webinar? Here are Investing.com’s top 10 stock picks for 2026
GRI Bio, Inc. (NASDAQ:GRI) announced Monday that it received a notice from the Nasdaq Stock Market Listing Qualifications Department stating the company is not in compliance with the minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market. The notification was based on information provided in GRI Bio’s quarterly report for the period ended September 30, 2025.
Nasdaq Listing Rule 5550(b)(1) requires companies with a market value of listed securities below $35 million and annual net income under $500,000 to maintain at least $2.5 million in stockholders’ equity. According to the company, it did not meet this threshold as of its most recent quarterly filing.
Under Nasdaq rules, GRI Bio has 45 calendar days from the date of the notice, or until January 10, 2026, to submit a plan to regain compliance. If the compliance plan is accepted, Nasdaq staff may grant an extension of up to 180 calendar days from the notice date to meet the equity requirement. The company stated it intends to submit such a plan.
The notice does not have an immediate effect on GRI Bio’s listing on the Nasdaq Capital Market, provided the company continues to meet other ongoing listing requirements. If the compliance plan is not accepted, GRI Bio’s common stock would be subject to delisting, although the company would have the opportunity to appeal the decision to a Nasdaq Hearing Panel.
This information is based on a statement in a press release filed with the Securities and Exchange Commission.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.